Press Releases
Excerpt from the Press Release: Agilent Technologies Inc. (NYSE: A) today announced cancer research innovations in cell analysis and genomics that will be on show at the American Association for Cancer Research Annual Meeting, being held April 8 – 13, 2022 in New Orleans, Louisiana. “Cancer research is an important focus area for Agilent. The AACR…
Read More
Excerpt from the Press Release: SAN FRANCISCO, April 08, 2022 (GLOBE NEWSWIRE) — T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced it is advancing its second TCR-T program, TK-2504, toward the clinic and presented preclinical data on its ability to generate novel TCRs targeting the KRASG12V antigen. The…
Read More
1,500 healthy volunteers to participate in a Phase II/III double-blind placebo-controlled study in India Study results to be submitted for Emergency Use Authorization (EUA) Vaccine is shelf stable for over six months at room temperature at 25° Celsius (77° Fahrenheit) and maintains potency for one month at 37° Celsius (99° Fahrenheit) Excerpt from the Press…
Read More
ADXS-PSA in combination with KEYTRUDA® in metastatic castration-resistant prostate cancer (mCRPC) is associated with prolonged overall survival in this population, particularly in patients with visceral metastasis Median overall survival of 16.4 months for patients with visceral metastases treated with ADXS-PSA in combination with KEYTRUDA® compared to ~9 months from historical data with KEYTRUDA® alone Median overall survival of 33.7…
Read More
Pilot aims to prevent symptoms in advance with contextualized data for cancer patient care Excerpt from the Press Release: (Carevive), the leading oncology-focused health technology company centered on understanding and improving the cancer patient experience, announced today a partnership with Blue Spark Technologies, a leader and an innovator in wearable wireless medical device solution The study…
Read More
If authorized by the FDA, the Proof Lab Test System may be used to deliver accurate, actionable, lab-quality results for COVID-19 (SARS-CoV-2) in as little as 18 minutes Excerpt from the Press Release: CAMBRIDGE, Mass., April 7, 2022 /PRNewswire/ — Proof Diagnostics, Inc., an innovative healthcare technology company delivering innovative solutions in molecular diagnostics, today announced the submission…
Read More
Bria-OTS™ would build on BriaCell’s existing clinical trial data with Bria-IMT™, treating each patient with the optimized pre-manufactured Bria-OTS™ formulation based on HLA-type. BriaCell and National Cancer Institute collaborating on Bria-OTS™, BriaCell’s off-the-shelf personalized immunotherapy, as a treatment for cancer. BriaCell to present Bria-OTS™ approach at the American Association for Cancer Research (AACR) Annual Meeting 2022. Excerpt from the…
Read More
Topline efficacy and safety data expected in first half of 2023 Excerpt from the Press Release: BRISBANE, Calif., April 07, 2022 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced the completion of enrollment in the…
Read More
Excerpt from the Press Release: OUTH SAN FRANCISCO–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and MediSix Therapeutics, a cell therapy company creating novel therapeutics to target T-cell leukemia and lymphoma, today announced a collaboration to discover novel antibodies against…
Read More
– Patent valid through 2038 – Phase IIb ALS trial expected to commence H1 2022 Excerpt from the Press Release: CAMBRIDGE, Mass., April 6, 2022 /PRNewswire/ — NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced the Canadian Intellectual Property Office has granted the Company a key patent titled “Compositions…
Read More